Oftan (Timolol)

Timolol, the active ingredient in Oftan, is a beta blocker presented as an ophthalmic solution for ocular use. It treats open‑angle glaucoma and ocular hypertension by lowering intra‑ocular pressure.

GNH USA supplies Oftan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Timolol is used in the management of ocular conditions that involve elevated intra‑ocular pressure.

Open‑angle glaucoma: reduces intra‑ocular pressure to slow disease progression. Ocular hypertension: lowers intra‑ocular pressure to prevent development of glaucoma. Secondary glaucoma: helps control pressure when other causes are present.

Timolol may cause ocular and systemic adverse reactions.

Common Side Effects: - Burning or stinging sensation in the eye - Blurred vision - Dry eye or reduced tear production - Conjunctival hyperemia (redness) - Temporary visual disturbances - Mild headache

Serious or Rare Side Effects: - Bradycardia or heart block - Systemic hypotension - Bronchospasm or worsening asthma - Severe allergic reaction (angio‑edema, anaphylaxis) - Cardiac failure or worsening heart disease - Depression or mood changes

Timolol requires careful assessment before and during therapy.

Assess cardiovascular status: check for bradycardia, heart block, or heart failure. Review respiratory history: avoid in patients with asthma or severe COPD. Monitor blood pressure: watch for systemic hypotension. Avoid concurrent non‑selective beta‑blockers: risk of additive cardiac effects. Store at room temperature: keep in original container, protect from light and moisture.

Timolol can interact with other systemic and ocular agents.

Major Interactions (Avoid): - Systemic non‑selective beta‑blockers (e.g., propranolol): additive cardiac depression. - Calcium channel blockers (e.g., verapamil): increased risk of AV block. - Antiarrhythmic drugs (e.g., amiodarone): enhanced bradycardia.

Moderate Interactions (Monitor Closely): - Topical adrenergic agonists (e.g., epinephrine eye drops): reduced efficacy. - Other ocular hypotensives (e.g., prostaglandin analogs): additive pressure‑lowering effect. - Systemic antihypertensives: may potentiate hypotensive response.